Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BiTE desensitization for highly sensitized kidney transplant candidates (cPRA ≥ 90%)
ChiCTR2600129635Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of blinatumomab and teclistamab in end-stage kidney disease (ESKD) and HLA sensitization (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Composite desensitization response rate. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
blinatumomabteclistamab
03
Conditions
end-stage kidney disease (ESKD)HLA sensitization
Beyond the preview
Go deeper on ChiCTR2600129635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129635.